Table 2 Prescription patterns for incretin-mimetics with analyzed covariables
Patients with statutory health insurance n = 6712 (92.0 %) | Patients with private health insurance n = 586 (8.0 %) | Statistical Significance (p-Wert) | |
|---|---|---|---|
Average age in years (± SD) | 69.9 ± 12.1 | 69.2 ± 12.1 | n. s. |
Sex (% female) | 53.8 | 31.1 | p < 0.0001 |
Morbidity (± SD) | 1.92 ± 1.78 | 1.44 ± 1.67 | p = 0.0008 |
Percentage of prescriptions for DPP-4 inhibitors (%) | 6.3 | 8.4 | p < 0.0001 |
Percentage of prescriptions for GLP-1 agonists (%) | 0.6 | 1.3 | p < 0.0001 |
Percentage of prescriptions for incretin-mimetics (%) (DPP-4-inhibitors or GLP-1-agonists) | 6.9 | 9.7 | p < 0.0001 |
Percentage of patients with at least one incretin-mimetic prescription in the observation period (%) | 15.3 | 21.0 | p < 0.0001 |
For these patients, in the observation period, there were also prescriptions for | |||
• Insulin, incl. premixed and analogues (%) | 24.8 | 15.4 | p = 0.0245 |
• Metformin as monotherapy (%) | 69.9 | 61.0 | p = 0.0497 |
• Sulfonylurea as monotherapy (%) | 30.4 | 14.6 | p = 0.0002 |